VBI 1501A

Drug Profile

VBI 1501A

Alternative Names: VBI-1501; VBI-1501A

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VBI Vaccines
  • Class Cytomegalovirus vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cytomegalovirus infections

Most Recent Events

  • 26 Jul 2018 VBI Vaccines plans a meeting with the regulatory bodies to advance the development of VBI 1501A in the second half of 2018
  • 26 Jul 2018 Updated immunogenicity data from a phase I trial in Cytomegalovirus infections released by VBI Vaccines
  • 24 Aug 2017 VBI Vaccines completes a phase I trial in Cytomegalovirus infections (Prevention, In volunteers) in Canada (NCT02826798)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top